.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Accenture
UBS
Healthtrust
Harvard Business School
Novartis
McKinsey
Citi
Cantor Fitzgerald
Farmers Insurance
Cerilliant

Generated: July 27, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Which drugs does patent 7,101,569 protect, and when does it expire?


Patent ► Subscribe protects LEVOXYL and is included in one NDA.

This patent has twenty-six patent family members in nine countries.

Summary for Patent: ► Subscribe

Title:Methods of administering levothyroxine pharmaceutical compositions
Abstract:The present invention generally relates to stable pharmaceutical compositions, and methods of making and administering such compositions. In one aspect, the invention features stabilized pharmaceutical compositions that include pharmaceutically active ingredients such as levothyroxine (T4) sodium and liothyronine (T3) sodium (thyroid hormone drugs), preferably in an immediate release solid dosage form. Also provided are methods for making and using such immediate release and stabilized compositions.
Inventor(s): Franz; G. Andrew (St. Louis, MO), Strauss; Elaine A. (Seminole, FL), DiMenna; Phillip A. (St. Petersburg, FL), Gemma; Rocco L. (Dover, OH)
Assignee:
Application Number:10/218,718
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
King Pharms
LEVOXYL
levothyroxine sodium
TABLET;ORAL021301-001May 25, 2001AB1,AB3RXYesNo► Subscribe► Subscribe METHOD OF USE OF ADMINISTERING LEVOTHYROXINE
King Pharms
LEVOXYL
levothyroxine sodium
TABLET;ORAL021301-002May 25, 2001AB1,AB3RXYesNo► Subscribe► Subscribe METHOD OF USE OF ADMINISTERING LEVOTHYROXINE
King Pharms
LEVOXYL
levothyroxine sodium
TABLET;ORAL021301-003May 25, 2001AB1,AB3RXYesNo► Subscribe► Subscribe METHOD OF USE OF ADMINISTERING LEVOTHYROXINE
King Pharms
LEVOXYL
levothyroxine sodium
TABLET;ORAL021301-004May 25, 2001AB1,AB3RXYesNo► Subscribe► Subscribe METHOD OF USE OF ADMINISTERING LEVOTHYROXINE
King Pharms
LEVOXYL
levothyroxine sodium
TABLET;ORAL021301-005May 25, 2001AB1,AB3RXYesNo► Subscribe► Subscribe METHOD OF USE OF ADMINISTERING LEVOTHYROXINE
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: ► Subscribe

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,555,581 Levothyroxine compositions and methods► Subscribe
7,067,148Stabilized pharmaceutical and thyroid hormone compositions and method of preparation► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia2002240394► Subscribe
Australia2002258397► Subscribe
Australia2002332507► Subscribe
Australia2002341555► Subscribe
Australia2002362468► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Federal Trade Commission
Baxter
Fuji
Cerilliant
Dow
Citi
Novartis
Queensland Health
Teva
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot